The present invention includes pharmaceutical composition comprising (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide)(diNACA) or D.sub.3-N-acetyl cysteine amide, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using diNACA to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuventation, antimicrobial infection, Friedreich's ataxia.

The present invention includes pharmaceutical composition comprising (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA), deuterated NACA-d3, deuterated di-NACA-d.sub.6, combinations thereof, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using diNACA, NACA-d3, di-NACA-d.sub.6, or combinations thereof, to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuvenation, antimicrobial infection, Friedreich's ataxia.

The present invention includes pharmaceutical composition comprising (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA), deuterated NACA-d3, deuterated di-NACA-d.sub.6, combinations thereof, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using diNACA, NACA-d3, di-NACA-d.sub.6, or combinations thereof, to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuvenation, antimicrobial infection, Friedreich's ataxia.

Various embodiments disclosed relate to a method of oxidizing sulfur-containing compounds. The method involves contacting a sulfur-containing compound with a helmet phthalocyaninato-type catalyst in the presence of an oxidant. The present invention also provides a method of removing undesired sulfur-containing compounds from a fluid, such as natural gas, crude oil or an aqueous waste stream.

Various embodiments disclosed relate to a method of oxidizing sulfur-containing compounds. The method involves contacting a sulfur-containing compound with a helmet phthalocyaninato-type catalyst in the presence of an oxidant. The present invention also provides a method of removing undesired sulfur-containing compounds from a fluid, such as natural gas, crude oil or an aqueous waste stream.

The present invention relates to a method for preparing methyl mercaptan, in batches or continuously, preferably continuously, said method including at least the following steps: a) reacting at least one hydrocarbon feedstock in the presence of hydrogen sulphide (H.sub.2S) and optionally sulphur (S) such as to form carbon disulphide (CS.sub.2) and hydrogen (H.sub.2); b) reacting said carbon disulphide (CS.sub.2) by hydrogenation in the presence of said hydrogen (H.sub.2) obtained in step a) such as to form methyl mercaptan (CH.sub.3SH), hydrogen sulphide (H.sub.2S) and possibly hydrogen (H.sub.2); c) optionally recirculating said hydrogen sulphide (H.sub.2S) formed during step b) to step a); and d) recovering the methyl mercaptan.

The present invention relates to a method for preparing methyl mercaptan, in batches or continuously, preferably continuously, said method including at least the following steps: a) reacting at least one hydrocarbon feedstock in the presence of hydrogen sulphide (H.sub.2S) and optionally sulphur (S) such as to form carbon disulphide (CS.sub.2) and hydrogen (H.sub.2); b) reacting said carbon disulphide (CS.sub.2) by hydrogenation in the presence of said hydrogen (H.sub.2) obtained in step a) such as to form methyl mercaptan (CH.sub.3SH), hydrogen sulphide (H.sub.2S) and possibly hydrogen (H.sub.2); c) optionally recirculating said hydrogen sulphide (H.sub.2S) formed during step b) to step a); and d) recovering the methyl mercaptan.

The present invention relates to a method for preparing methyl mercaptan, in batches or continuously, preferably continuously, said method including at least the following steps: a) reacting at least one hydrocarbon feedstock in the presence of hydrogen sulphide (H.sub.2S) and optionally sulphur (S) such as to form carbon disulphide (CS.sub.2) and hydrogen (H.sub.2); b) reacting said carbon disulphide (CS.sub.2) by hydrogenation in the presence of said hydrogen (H.sub.2) obtained in step a) such as to form methyl mercaptan (CH.sub.3SH), hydrogen sulphide (H.sub.2S) and possibly hydrogen (H.sub.2); c) optionally recirculating said hydrogen sulphide (H.sub.2S) formed during step b) to step a); and d) recovering the methyl mercaptan.

The present invention includes methods for making and isolating N-acetylcysteine amide, (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide, diNACA), intermediates and derivatives thereof comprising: contacting cystine with an alcohol and a chlorinating reagent to form an organic solution containing L-cystine dimethylester dihydrochloride; combining dried or undried L-cystine dimethylester dihydrochloride with a triethylamine, an acetic anhydride, and an acetonitrile to form a di-N-acetylcystine dimethylester; mixing dried di-N-acetylcystine dimethylester with ammonium hydroxide to form a di-N-acetylcystine amide (diNACA); and separating dried di-N-acetylcystine dimethylester into N-acetylcysteine amide with dithiothreitol, triethylamine and an alcohol.

The present invention includes methods for making and isolating N-acetylcysteine amide, (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide, diNACA), intermediates and derivatives thereof comprising: contacting cystine with an alcohol and a chlorinating reagent to form an organic solution containing L-cystine dimethylester dihydrochloride; combining dried or undried L-cystine dimethylester dihydrochloride with a triethylamine, an acetic anhydride, and an acetonitrile to form a di-N-acetylcystine dimethylester; mixing dried di-N-acetylcystine dimethylester with ammonium hydroxide to form a di-N-acetylcystine amide (diNACA); and separating dried di-N-acetylcystine dimethylester into N-acetylcysteine amide with dithiothreitol, triethylamine and an alcohol.